Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Company Overview - Ovid Therapeutics Inc. is a biopharmaceutical company based in New York, focused on developing small molecule medicines for brain conditions with significant unmet needs [2] - The company is advancing a pipeline of novel, targeted small molecule candidates that address neuronal hyperexcitability associated with various neurological and neuropsychiatric disorders [2] Product Pipeline - Ovid is developing OV329, a next-generation GABA-aminotransferase inhibitor, aimed at treating treatment-resistant seizures and other undisclosed indications [2] - The company is also working on OV350, OV4071, and additional compounds that activate the KCC2 transporter for multiple central nervous system disorders [2] Upcoming Events - Company management will participate in the BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025 [1]